Geneva Private Equity

Geneva Private Equity

Geneva Private Equity operates from the Swiss financial hub whose name it carries, concentrating on a single transaction profile: acquiring controlling positions in profitable, family-owned European companies where succession or growth capital creates an entry point. The firm targets the lower mid-market, a segment dense with engineering-intensive businesses that lack obvious internal buyers. Its capital base draws on Swiss private wealth and select European family offices, though the partnership has never publicly disclosed total committed capital. The portfolio reveals a bias toward tangible industrial assets and consumer-facing niche leaders. Confirmed direct investments include Proderma, a Swiss medical devices group specialized in dermatology and aesthetics, and Premi, an Italian manufacturer of luxury secondary packaging serving high-end spirits and cosmetics brands (public record). The firm also holds Mecasonic, a French ultrasonic welding equipment producer that supplies automotive and packaging lines — a position consistent with Geneva's preference for technical manufacturing. It sources primarily through proprietary networks, relying on Geneva-based wealth managers, industrial advisors, and direct founder outreach rather than auction processes. Geneva Private Equity maintains a lean structure consistent with its concentrated portfolio approach. The leadership team under Thierry de Roucy operates from a single office in Geneva. Alongside the equity platform, related entrepreneurial activity includes co-investment with European family offices on a deal-by-deal basis. In September 2024, the firm acquired Groupe Graphito, a French leader in industrial printing and marking on primary packaging, expanding its manufacturing and industrials footprint. The firm operates in a competitive pocket of the European market — between local family offices writing direct checks and the large-cap buyout funds that have moved downmarket — but survives on a sourcing advantage and patience. Unlike institutional funds, Geneva does not face a fixed fund life; it deploys permanent capital from aligned families, allowing it to hold portfolio companies for cycles long enough to execute multi-year operational turnarounds without the pressure of a defined exit clock.